| scholarly article | Q13442814 |
| P356 | DOI | 10.1023/B:PHAM.0000048203.30568.81 |
| P698 | PubMed publication ID | 15587934 |
| P2093 | author name string | Wei Wang | |
| Ying Ou | |||
| Yanggu Shi | |||
| P2860 | cites work | Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice | Q28362795 |
| Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris. | Q30717140 | ||
| Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study | Q33186937 | ||
| Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys | Q34155234 | ||
| Nesiritide for the treatment of decompensated heart failure | Q34192826 | ||
| An update on nesiritide for treatment of decompensated heart failure | Q34232053 | ||
| Prediction of sequential antigenic regions in proteins | Q34377036 | ||
| BNP in decompensated heart failure: diagnostic, prognostic and therapeutic potential | Q34470999 | ||
| Immune and neurohormonal pathways in chronic heart failure | Q34513186 | ||
| Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration | Q34869987 | ||
| Safety and efficacy of nesiritide for the treatment of decompensated heart failure. | Q35002257 | ||
| Nesiritide: a review of its use in acute decompensated heart failure | Q35028379 | ||
| Nesiritide: a new therapy for the treatment of heart failure | Q35096099 | ||
| B-type natriuretic peptide: spectrum of application. Nesiritide (recombinant BNP) for heart failure | Q35566119 | ||
| Nesiritide in perspective: evolving approaches to the management of acute decompensated heart failure | Q35605489 | ||
| Nesiritide therapy for acute heart failure | Q35632544 | ||
| Cardiac fibrosis in mice lacking brain natriuretic peptide | Q35677878 | ||
| Nesiritide for the treatment of congestive heart failure | Q35753426 | ||
| Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide | Q35915041 | ||
| Neurohormonal systems during progression of heart failure: a review | Q40619147 | ||
| An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates | Q40663794 | ||
| Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression | Q40725769 | ||
| The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. | Q40935969 | ||
| Neurohormonal modulation in heart failure: ACE inhibition and beyond | Q41016864 | ||
| Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease | Q41057169 | ||
| Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study | Q41690802 | ||
| In vivo metabolism of brain natriuretic peptide in the rat involves endopeptidase 24.11 and angiotensin converting enzyme | Q41859481 | ||
| The antihypertensive response to lisinopril: the effect of age in a predominantly black population | Q41937935 | ||
| B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening | Q44274431 | ||
| The use of nesiritide in the management of acute decompensated heart failure | Q44452892 | ||
| Nesiritide in acute heart failure | Q44597889 | ||
| Effect of albumin fusion on the biodistribution of interleukin-2 | Q44659989 | ||
| Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure | Q44853867 | ||
| Relationship between the suppressive actions on intestinal absorption and on cGMP production for the natriuretic peptide family in dogs | Q48184579 | ||
| Nesiritide in acute heart failure | Q48188003 | ||
| Use of nesiritide to treat acute decompensated heart failure. | Q48362851 | ||
| Examination of the in vivo cardiac electrophysiological effects of nesiritide (human brain natriuretic peptide) in conscious dogs | Q48455778 | ||
| Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure | Q48578854 | ||
| Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial | Q48649829 | ||
| Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep | Q48956540 | ||
| Brain natriuretic peptide administered to man: actions and metabolism | Q49042771 | ||
| A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro | Q49868872 | ||
| Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. | Q53907769 | ||
| Comparative bioactivity of atrial and brain natriuretic peptides in an ovine model of heart failure | Q73129380 | ||
| Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs | Q73377155 | ||
| Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys | Q78569532 | ||
| Nesiritide in acute heart failure | Q79086074 | ||
| P433 | issue | 11 | |
| P921 | main subject | heart failure | Q181754 |
| congestive heart failure | Q19000661 | ||
| P304 | page(s) | 2105-2111 | |
| P577 | publication date | 2004-11-01 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure | |
| P478 | volume | 21 |
| Q33414424 | Addition of a sequence from alpha2-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis |
| Q37027164 | Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. |
| Q95660687 | Cardiac natriuretic peptides |
| Q37399482 | Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension |
| Q37807056 | Engineering of Therapeutic Proteins Production in Escherichia coli |
| Q33625084 | Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats |
| Q38116457 | IL-1Ra and its delivery strategies: inserting the association in perspective. |
| Q37591452 | Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs |
| Q79440172 | Influence of processing conditions on the physical state of mannitol--implications in freeze-drying |
| Q37258795 | Insights into natriuretic peptides in heart failure: an update |
| Q36794409 | Natriuretic peptides and therapeutic applications |
| Q33878162 | Nesiritide in acute decompensated heart failure: current status and future perspectives |
| Q36669295 | Novel therapeutic directions for the natriuretic peptides in cardiovascular diseases: what's on the horizon |
| Q37587761 | Paracrine cross-talk between skeletal muscle and macrophages in exercise by PGC-1α-controlled BNP |
| Q37033032 | Pharmacokinetics of recombinant bifunctional fusion proteins |
| Q37167803 | The role of natriuretic peptides in heart failure |
| Q81888133 | The role of natriuretic peptides in heart failure |
Search more.